ahead earn updat
model anticip potenti beat padcev dupix eylea
sector perform pt see potenti top-lin beat driven larg base biz
model slight revenu beat vs st despit usual weakness/
season non-gaap opex vs st non-gaap net incom vs st
non-gaap dilut ep vs st factset note stockpil effect
might help due pandem aimovig script shown high single-digit q/
 growth expect higher model vs st cautiou
neulasta revenu estim vs st biosimilar ziextenzo sandoz/
nv market launch enbrel model in-lin revenu vs st recal sandoz
appeal rule district court side enbrel ip continu
expect posit outcom appeal process model in-lin otezla
revenu vs st visiblealpha see possibl revis
revenu non-gaap ep guidanc downward account
pandem impact larg limit
sector perform rais pt dupix continu strong demand
growth like set anoth compel despit season headwind new impact
dupix eylea remain focu ahead report sni report dupi apr im
script track analysi indic anoth strong quarter follow link dupix eylea
us dupi script vs us eylea script q/q though histor
eylea script avail track repres small portion total sale model eylea us
sale q/q vs st estim driven primarili tailwind recent
beovu safeti issu link howev cautious watch impact overal anti-
vegf market total number intravitr inject may reduc due less frequent patient
visit compromis dri efficaci concern patient safeti think impact
like becom sever eylea sale benefit beovu setback model
dupix global sale q/q vs st estim reflect q/q script
growth top line model total revenu vs st st
estim stem recent announc account chang model updat updat
model new account rule signific increas eylea dupix revenu estim
out-year reflect current strong demand growth competit headwind live
concern increas pt maintain sector perform rate
price prior trade day market close estimate unless otherwis note
valu usd unless otherwis note
capit market appreci consider institut investor all-america research survey
outperform pt expect stabl base busi season
anticip increas focu valrox ahead launch model
in-lin revenu vs st in-lin ep vs st
model palynziq revenu vs st see growth new
pku patient might slow patient naglazym could see season
lumpi larg line st vs st consensu continu
see attract setup valrox beat consensu estim ahead
anticip launch pdufa august even though price remain
unknown see note
outperform new pt focu ultomiri switch
pnh ahu patient see upsid potenti ultomiri revenu beat despit
load dose impact pnh patient model soliri revenu slightli
st estim anticip impact switch patient ultomiri
continu off-set growth neurolog indic gmg
nmosd anticip uptak soliri may slower nmosd popul vs gmg
due inconveni biweekli dose highlight recent kol call see ny day
note total soliri treat neurolog patient could exceed march vs
patient report dec small contribut nmosd
model ultomiri revenu vs st switch pnh ahu
patient continu help load dose dynam note switch rate us
pnh patient might slow latest updat show patient switch
track comfort achiev convers goal end accord
estim expect initi phase ahu switch rate us track
similarli pnh switch load dose dynam may lead limit price
headwind model chang increas ultomiri revenu estim
vs previou given high switch rate ahu patient similar initi stage
pnh switch us increas pt maintain outperform rate
outperform new pt focu padcev tukysa
launch dynam physician feedback see upsid enthusiast earli
adopt bladder cancer set see larg in-lin quarter adcetri
model adcetri revenu slightli st factset follow
disappoint adcetri without account demand growth
believ adcetri sale could still grow q/q help price hike
end expect padcev us sale vs st expect
rapid uptak padcev metastat urotheli cancer muc shown highli
impress respons rate see chicago day note recent approv tukysa
tucatinib mbc model revenu vs previou
assumpt market launch near-term focu remain readout
innovatv studi tisotumab vedotin recurrent/metastat cervic cancer
model chang recent increas us padcev revenu estim
script track indic strong launch us estim addit
increas treatment durat padcev metastat patient cycl vs previou
pre-metastat muc patient cycl vs previou cycl updat
tukysa tucatinib gross price estim per patient per month vs previou
highlight management confer call post approv
decreas market penetr tukysa mbc set vs previou
result increas pt maintain outperform rate
outperform pt focu tibsovo usag aml could
add tailwind estim model tibsovo revenu q/q
growth in-lin vs st visiblealpha idhifa royalti vs st tibsovo
revenu help increas treatment durat increas penetr
rraml aml set see investor focu shift mitapivat
readout thalassemia sickl cell diseas indic
importantli readout activ activate-t pkd expect
pkd indic mitapivat would key revenu growth driver start
outperform pt unchang see potenti cabometyx beat
script analysi price increas tailwind impact clinic trial
recruit focu call im script track analysi indic q/q
demand declin compar slightli unfavor overal tki space
grown total script inlyta/axitinib grow like due io combo
increas revenu estim vs st consensu
reflect current script trend price hike quarter jan
model slight decreas volum demand lose market share axipembro frontlin
rcc call watch management commentari potenti impact
busi oper especi timelin updat recent cabo io
trial contact collabor roch et al model updat
increas revenu estim reflect current price script
trend pt remain outperform rate
sector perform pt remain cautiou around reblozyl launch beta-
thalassemia due limit market size us model reblozyl revenu
vs st visiblealpha beta-thalassemia indic given small patient
popul beta-thalassemia patient us dont expect major inflect
reblozyl revenu meaning contribut recent approv md indic
start reblozyl sale estim near-term focu remain
detail data sotatercept pah at confer may
outperform specul risk pt cautiou around
palforzia revenu given earli stage launch potenti neg impact
model palforzia revenu line st estim due
week sell post-approv see note neg impact
pandem initi sign-up allergi doctor allergi practic
palforziarem websit encourag famili might delay treatment initi
order avoid visit clinic facil pandem us
sector perform specul risk pt focu remain pivot
readout vadadustat expect in-lin quarter auryxia
model auryxia sale line st estim consist script
track howev script growth decreas q/q vs
prior author requir could serv addit headwind see
readout studi vadadustat major potenti catalyst
respect remain confid vadadustat achiev non-
inferior aranesp efficaci safeti endpoint mace event
opportun impact nerlynx prescript summit trial enrol
focu call model in-line/slight beat estim
nerlynx sale q/q slightli st estim vs management prior guidanc
model volum bottl sold decreas benefit
price hike price impact consid quarter impact
howev gross-to-net remain concern call watch management commentari
nerlynx sale contribut recent approv mbc set commentari
around impact patient prescript importantli delay halt
summit trial due current situat model updat increas nerlynx
estim price impact also increas assumpt
out-year reflect current trend pt remain weight averag
sotp dcf valuat maintain sector perform specul risk rate
slight beat rubraca potenti impact busi oper expens
focus call increas rubraca revenu estim prior
price increas jan model continu rubraca growth
sale q/q follow q/q link note vs st estim
rubraca estim includ us sale q/q eu sale
q/q im script analysi rubraca prescript indic q/
 growth us demand ruca script data becam avail late aug see
continu us growth trajectori follow slight set-back though want
cautiou around stockpil due current situat may
revers call watch management commentari impact rubraca
prescript well busi oper updat expens guidanc
due current situat model updat adjust rubraca revenu estim
count-in recent price hike increas gtn pt remain maintain
valu dcf basi use wacc termin growth rate
assum trade discount valu forward price-to-earnings basi vs peer similar growth
prospect discount project revenu legaci product contribut
discount revenu growth product contribut discount risk-adjust
revenu pipelin product contribut discount revenu biosimilar
product contribut net cash contribut result price
target support sector perform rate
base case sum-of-the-part valuat base pos-adjust npv eylea
dupix blend po kevzara praluent libtayo assumpt support
price target sector perform rate
base-cas dcf-deriv valuat base pos-adjust npv base
busi vimizim naglazym kuvan aldurazym firdaps brineura diseas
po palynziq pku po vosoritid achondroplasia po
hemophilia po util discount rate termin growth rate
line biotechnolog compani sustain base busi result
price target support outperform rate
price target base discount cash flow dcf methodolog
use conserv termin growth rate differ program contribut
follow soliri sale pnh soliri sale ahu strensiq
sale kanuma sale lal-d soliri sale gmg
share soliri sale nmo ultomiri sale pnh ultomiri sale
ahu ultomiri sale neuro sale wilson diseas
sale danicopan net cash
price target support outperform rate
price target deriv dcf free cash flow gener pos-
adjust commerci product pipelin royalty/mileston forecast
model adcetri us sale grow larg growth hl us
us ctcl us model ev us sale
mbc mbc pre-metastat muscle-invas uc tukysa tucatinib mbc
revenu assign addit valu tv tucatinib pipelin mcrc
util discount rate assign termin valu target price
support outperform rate
base case dcf-deriv valuat base po adjust npv idhifa
sale estim rraml po us po eu aml po us/
eu ivosidenib rraml po us po eu aml po us/eu
cholangiocarcinoma po glioma po pkd po
mtap-delet tumor po util discount rate line
smid-cap biotechnolog compani pt support outperform rate
base-cas dcf-deriv valuat base pos-adjust npv cabozantinib
sale mtc po rcc rcc po po mcrpc
po cotel revenu royalti melanoma po util discount
rate line smid-cap biotechnolog compani assumpt support
price target outperform rate
pt base discount cash flow dcf analysi support sector
perform rate util discount rate given develop risk see
reblozyl md -thalassemia addit pipelin prospect consid upsid
estim encompass follow reblozyl sale launch beta-thalassemia us
md launch eu annual net price us
eu mo treatment -thalassemia po eu us
base case dcf-deriv valuat base pos-adjust npv palforzia sale
peanut allergi desensit po us po eu util discount
rate line clinical-stag biotechnolog compani assumpt support
price target outperform rate given valuat driven sale singl
pre-commerci earli stage asset assign specul risk qualifi rate
price target base discount cash flow dcf analysi support
sector perform rate includ specul risk qualifi given akba valuat driven
primarili pipelin asset vadadustat trial util discount rate given
develop risk see vadadustat ckd line smid-cap biotechnolog
compani includ termin valu addit pipelin prospect upsid
model revenu estim base anticip regulatori approv vadadustat
usa eu japan rest world expect us/eu ckd launch po
us/jp eu
current valu use blend averag probability-adjust
discount cash flow analysi use industry-standard wacc valuat
sum-of-the-part approach valuat valu neratinib opportun adjuv
po us ex-u metastat po breast
cancer set plu compani net cash posit pt support
sector perform rate given valuat compris sale one product assign
base-cas dcf-deriv valuat base pos-adjust npv rubraca sale
treatment ovarian cancer po us po eu mainten
ovarian cancer po us eu mainten ovarian cancer po
us eu mcrpc po us eu chemo-na mcrpc po
us eu post-chemo mcrpc util discount rate assumpt
support price target outperform specul risk rate add specul risk
qualifi account risk associ convert debt
compani report capit market estim
chang model revenu expens expens expens incom incom expens incom incom non- non-
compani report capit market estim
incom statement mm fy soliri net ultomiri sale net danicopan sale net complement net strensiq net kanuma net sale risk adjust net metabol sale mg- sale waiha- net revenues- net product contract research revenues- total other- gross sg impair intang amort purchas intang chang fair valu conting acquisition-rel costs- restructur total oper oper incom loss oper incom invest interest foreign currenc gain loss debt exchang expense- net incom incom tax tax net incom basic ep dilut
compani report capit market estim
valuat tax pv fcfe termin total ye net ye
compani report capit market estim
compani report capit market estim
chang model us revenu us revenu revenu revenu expens expens expens incom incom expens incom gaap
compani report capit market estim
million except per share us/canada ex-u ex-u vedotin tucatinib contract licens fee good gener oper incom incom expens interest incom incom incom outstand basic outstand dilut
compani report capit market estim
compani report capit market estim
valuat tax pv fcfe hlhl con post-tfirst-lin hlr/r alclfirst-lin ptclctcldlbclptclpadcevtisotumab royaltiescashtotaladcetri
compani report capit market estim
compani report capit market estim
account rulenew account rulenet product sale sale sale collabor healthcar collabor revenu includ expens cog oper incom expens oper expens incom income/expens invest incom expens incom expens expens incom taxprovis incom tax incom tax rate incom loss incom loss ep ep ep ep
compani report capit market estim
eylea net stage valu dilut share outstand net cap market sum-of-the-part valuat
compani report capit market estim
compani report capit market estim
dollar except share per share mtc us rcc us revenu us revenu mcrpc us cabometyx cabometyx cotel collabor collabor collabor collabor oper expens research gener oper incom incom incom incom benefit provis incom tax rate incom loss basic dilut
compani report capit market estim
discount rate equiti except per-shar data discount add add effect add includ exclud /share exclud rcccabo hcccabo mtccabo
compani report capit market estim
chang model revenu revenu expens profit expens expens incom incom expens incom gaap
compani report capit market estim
incom statementdollar million except per share us q/q y/i eu royalti sales- total row royalti sales- global neratinib licens total gross research sell gener total oper oper incom incom expens interest incom incom pre-tax incom benefit provis incom tax- effect tax incom ep ep dilut
exhibit valuat pt averag dcf sotp valuat
compani report capit market estim
discount rate equiti except per-shar data discount add add effect add incl valueprob successpeak sale mm neratinib adjuv adjuv metastat metastat net net valu dilut share outstand net per share market sum-of-the-part
compani report capit market estim
chang model revenu expens profit expens expens incom incom expens incom gaap
compani report capit market estim
clovi oncolog annual incom statement dollar except share per share ovarian rubraca ovarian eu rubraca prostat us rubraca prostat eu other- total product intang asset expens research sell gener acquir in-process research development- impair intang assets- chang fair valu conting purchas consideration- oper total oper incom income- interest eign currenc gain loss -- -- incom expens -- -- incom expens pre-tax incom incom tax incom loss basic dilut
compani report capit market estim
